Par Drugs And Stock Fundamentals
| PAR Stock | 290.40 11.35 4.07% |
Par Drugs And fundamentals help investors to digest information that contributes to Par Drugs' financial success or failures. It also enables traders to predict the movement of Par Stock. The fundamental analysis module provides a way to measure Par Drugs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Par Drugs stock.
At present, Par Drugs' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 579.2 M, whereas Total Revenue is forecasted to decline to about 669.2 M. Par | Select Account or Indicator |
Par Drugs And Company Return On Equity Analysis
Par Drugs' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Par Drugs Return On Equity | 0.21 |
Most of Par Drugs' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Par Drugs And is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Par Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Par Drugs And has a Return On Equity of 0.2084. This is 100.87% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all India stocks is 167.23% lower than that of the firm.
Par Drugs And Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Par Drugs's current stock value. Our valuation model uses many indicators to compare Par Drugs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Par Drugs competition to find correlations between indicators driving Par Drugs's intrinsic value. More Info.Par Drugs And is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.66 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Par Drugs And is roughly 1.51 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Par Drugs' earnings, one of the primary drivers of an investment's value.Par Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Par Drugs' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Par Drugs could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics of similar companies.Par Drugs is currently under evaluation in return on equity category among its peers.
Par Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 3.39 B | ||||
| Shares Outstanding | 12.3 M | ||||
| Price To Book | 3.69 X | ||||
| Price To Sales | 3.43 X | ||||
| Revenue | 956.4 M | ||||
| Gross Profit | 457.57 M | ||||
| EBITDA | 229.53 M | ||||
| Net Income | 145.01 M | ||||
| Total Debt | 159.79 M | ||||
| Book Value Per Share | 78.69 X | ||||
| Cash Flow From Operations | 202.49 M | ||||
| Earnings Per Share | 14.84 X | ||||
| Number Of Employees | 122 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.57 B | ||||
| Total Asset | 1.02 B | ||||
| Retained Earnings | 625.51 M | ||||
| Working Capital | 471.85 M | ||||
| Net Asset | 1.02 B |
About Par Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Par Drugs And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Par Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Par Drugs And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 51 K | 48.5 K | |
| Total Revenue | 956.4 M | 669.2 M | |
| Cost Of Revenue | 346.5 M | 413.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.